ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

Nicola R Hardwick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.